Trabedersen shows excellent protection and encouraging survival results in patients with advanced solid tumors , concludes Dr. Hubert Heinrichs, Chief Medical Officer at Antisense Pharma. In comparison to current treatments for late stage pancreatic carcinoma or malignant melanoma, our compound might prove to be an extremely novel and attractive therapeutic alternative. .. Antisense Pharma presents data from trabedersen Stage I/II cancer research at ASCO 2012 The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant colorectal or melanoma cancer at the international cancer congress ASCO 2012 in Chicago, USA .e.Goodwin is a former mind of the National Institute of Mental Health insurance and a medical professor of psychiatry at George Washington University. Caron, Ph.D., 2013 Lieber Prize for Outstanding Accomplishment in Schizophrenia Study, Duke University. Dr. Caron will show analysis in his laboratory which has shown that clinically effective antipsychotics block the activities of the neurotransmitter dopamine by getting together with dopamine D2 receptors, which are people of a large category of proteins known as G protein-coupled receptors . Dr. Caron and his co-workers have determined a novel setting of signaling for dopamine D2 receptors and so are exploring the way the findings could be leveraged to develop even more selectively targeted and effective antipsychotics.D., Ph.D., 2013 co-recipient of the Sidney R.